New Therapeutics to Treat Castrate-Resistant Prostate Cancer
The effective treatment of castrate-resistant prostate cancer (CRPC) has proven to be very challenging. Until recently, docetaxel was the only therapeutic demonstrated to extend overall patient survival. Yet recently, a considerable number of new therapeutics have been approved to treat CRPC patient...
Saved in:
Main Authors: | Ömer Acar, Tarık Esen, Nathan A. Lack |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2013-01-01
|
Series: | The Scientific World Journal |
Online Access: | http://dx.doi.org/10.1155/2013/379641 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
New Horizons In The Treatment Of Metastatic Castrate Resistant Prostate Cancer
by: Zein El Amir
Published: (2023-06-01) -
Identification of mitochondrial carrier homolog 2 as an important therapeutic target of castration-resistant prostate cancer
by: Yankui Liu, et al.
Published: (2025-02-01) -
The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer
by: Jennifer H. Gunter, et al.
Published: (2012-01-01) -
Role of Signaling Transduction Pathways in Development of Castration-Resistant Prostate Cancer
by: Takahiro Inoue, et al.
Published: (2011-01-01) -
HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
by: Goran Bencina, et al.
Published: (2023-06-01)